Who Paid My Doc
Yu-Po Lee
Orthopaedic Surgery of the Spine Orange, CA Medical Doctor
NPI 1598780025 CMS profile 72549
101 The City Dr S Bldg 29A, Orange, CA 92868
General payments
$62,901
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$77,030
Through program year 2025, Yu-Po Lee of Orange, CA is reported in the CMS Open Payments database as having received $62,901 across 67 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $77,030 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 72nd percentile of Orthopaedic Surgery of the Spine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $4,139 | 12 | |
| 2024 | General | $827 | 8 | |
| 2023 | General | $8,814 | 7 | |
| 2022 | General | $26,464 | 17 | |
| 2021 | General | $6,642 | 10 | |
| 2020 | General | $24 | 1 | |
| 2019 | General | $15,992 | 12 |
Beside peers
- Yu-Po Lee
- Orthopaedic Surgery of the Spine median
- Middle half of Orthopaedic Surgery of the Spine
- National median
In program year 2025, general payments to Yu-Po Lee were reported at $4,139. Among 1,704 Orthopaedic Surgery of the Spine profiles paid that year, the median was $2,061 and the middle half received between $347 and $14,651.
Show as a table
| Year | Yu-Po Lee | Orthopaedic Surgery of the Spine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $15,992 | $2,106 | $337–$18,608 | $163 |
| 2020 | $24 | $1,213 | $156–$15,082 | $114 |
| 2021 | $6,642 | $1,834 | $271–$15,617 | $132 |
| 2022 | $26,464 | $2,015 | $320–$17,036 | $149 |
| 2023 | $8,814 | $1,925 | $336–$14,599 | $160 |
| 2024 | $827 | $2,110 | $341–$12,483 | $164 |
| 2025 | $4,139 | $2,061 | $347–$14,651 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 27 drugsPart D claims
1,301
Drug cost
$28,892
Branded share of claims
20.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Oxycodone Hcl | Generic | 218 | $6,184 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 180 | $6,071 | |
| Lidocaine | Generic | 29 | $3,328 | |
| Gabapentin | Generic | 170 | $2,197 | |
| Celecoxib | Generic | 51 | $2,045 | |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | Brand | 70 | $1,786 | |
| Naloxone Hcl | Generic | 22 | $1,037 | |
| Tramadol Hcl | Generic | 66 | $906 | |
| Cyclobenzaprine Hcl | Generic | 54 | $893 | |
| Morphine Sulfate Er Morphine Sulfate | Brand | 16 | $577 |
The 10 drugs with the highest cost, of 27 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 50 billing codesPaid by Medicare
$260,381
Medicare patients
530
Services billed
1,751
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 75% | |
| Osteoporosis | 36% | |
| Diabetes | 35% | |
| Depression | 31% | |
| Ischemic heart disease | 30% | |
| Chronic kidney disease | 25% | |
| Atrial fibrillation | 19% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
67 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Orthopaedic Surgery of the Spine in California
Hyun Bae
Orthopaedic Surgery of the Spine · Santa Monica, CA
Choll Kim
Orthopaedic Surgery of the Spine · San Diego, CA
Stacey Bederman
Orthopaedic Surgery of the Spine · Orange, CA
Gregory Mundis
Orthopaedic Surgery of the Spine · La Jolla, CA
Paul Slosar
Orthopaedic Surgery of the Spine · Daly City, CA
Babak Barcohana
Orthopaedic Surgery of the Spine · Van Nuys, CA
Related records
Orthopaedic Surgery of the Spine in California
Practitioners in the same specialty and state, ranked by reported value.
All Orthopaedic Surgery of the Spine
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.